Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

NCT ID: NCT01553123

Last Updated: 2013-02-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether ulipristal acetate is effective in the treatment of females with anemia associated with uterine leiomyomas. The safety of this product will also be evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, placebo controlled, multicenter study with parallel groups in order to evaluate the efficacy and safety of ulipristal acetate in female subjects with anemia associated with uterine leiomyomas. The objective of this study is to determine if daily ulipristal acetate with iron is more effective than iron alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leiomyomas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ulipristal with iron

Group Type EXPERIMENTAL

Ulipristal Acetate

Intervention Type DRUG

once daily, oral

Iron

Intervention Type DRUG

once daily, dried ferrous sulfate

Placebo

Placebo with iron

Group Type PLACEBO_COMPARATOR

Iron

Intervention Type DRUG

once daily, dried ferrous sulfate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ulipristal Acetate

once daily, oral

Intervention Type DRUG

Iron

once daily, dried ferrous sulfate

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UPA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is a pre-menopausal female, 18 - 50 years;
* Has documented leiomyoma(s);
* Has leiomyoma-related anemia;
* Has an endometrial biopsy within the screening period prior to the first dose of the test article which shows no endometrial hyperplasia;
* Is willing and able to provide written informed consent and authorization to disclose protected health information.

Exclusion Criteria

* Has a history of uterine surgery that would interfere with the study;
* Has a condition requiring immediate or intermittent blood transfusions;
* Has a known coagulation disorder;
* Has a history of uterine, cervix, ovarian, or breast cancer;
* Has used a selective progesterone receptor modulator or a gonadotrophin releasing hormone agonist in previous 6 months;
* Has received blood transfusion within 8 weeks before the screening visit;
* Has abnormal liver functions;
* Is pregnant.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Watson Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Howard Zobrist, MS, PhD

Role: STUDY_DIRECTOR

Watson Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Site Status

Coastal Clinical Research, Inc

Mobile, Alabama, United States

Site Status

Women's Health Research

Phoenix, Arizona, United States

Site Status

Visions Clinical Research

Tucson, Arizona, United States

Site Status

Benchmark Research

Sacramento, California, United States

Site Status

Sharp Rees-Stealy Medical Group

San Diego, California, United States

Site Status

Medical Center for Clinical Research

San Diego, California, United States

Site Status

Downtown Women's Health Care

Denver, Colorado, United States

Site Status

Visions Clinical Research

Boynton Beach, Florida, United States

Site Status

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Site Status

Altus Research

Lake Worth, Florida, United States

Site Status

Healthcare Clinical Data, Inc.

North Miami, Florida, United States

Site Status

All Women's Healthcare of West Broward

Plantation, Florida, United States

Site Status

Physician Care Clinical Research, LLC

Sarasota, Florida, United States

Site Status

Comprehensive Clinical Trials, LLC

West Palm Beach, Florida, United States

Site Status

Atlanta Women's Research Institute, Inc

Atlanta, Georgia, United States

Site Status

Mount Vernon Clinical Research, LLC

Sandy Springs, Georgia, United States

Site Status

Fellows Research Alliance

Savannah, Georgia, United States

Site Status

Women's Health Practice

Champaign, Illinois, United States

Site Status

Advanced Gynecologic Surgery Institute

Naperville, Illinois, United States

Site Status

Center for Women's Research

Palos Heights, Illinois, United States

Site Status

South Bend Clinical

Granger, Indiana, United States

Site Status

Praetorian Pharmaceutical Research, LLC

Marrero, Louisiana, United States

Site Status

Women Under Study, LLC

New Orleans, Louisiana, United States

Site Status

Hutzel Womens Health Specialists

Detroit, Michigan, United States

Site Status

Women's Clinic of Lincoln, P.C.

Lincoln, Nebraska, United States

Site Status

Office of Annette Mayes, MD, PC

Las Vegas, Nevada, United States

Site Status

Office of Edmond Pack, MD

Las Vegas, Nevada, United States

Site Status

Office of R. Garn Mabey, Jr

Las Vegas, Nevada, United States

Site Status

Lawrence Obstetrics-Gynecology Clinical Research

Lawrenceville, New Jersey, United States

Site Status

Southwest Clinical Research

Albuquerque, New Mexico, United States

Site Status

New York Center for Women's Health Research

New York, New York, United States

Site Status

Carolina Women's Research and Wellness Center

Durham, North Carolina, United States

Site Status

Physicians for Women of Greensboro

Greensboro, North Carolina, United States

Site Status

Eastern Carolina Women's Center

New Bern, North Carolina, United States

Site Status

Wake Research Associates

Raleigh, North Carolina, United States

Site Status

PMG Research of Wilmington

Wilmington, North Carolina, United States

Site Status

Hawthorne Medical Research

Winston-Salem, North Carolina, United States

Site Status

Columbus Center for Women's Health Research

Columbus, Ohio, United States

Site Status

Advanced Clinical Concepts

West Reading, Pennsylvania, United States

Site Status

Southeast Regional Research Group

Aiken, South Carolina, United States

Site Status

South Carolina Clinical Research Center, LLC

Columbia, South Carolina, United States

Site Status

Discovery Clinical Trials - Genesis Health Central Women's Care

Dallas, Texas, United States

Site Status

Advances in Health Inc

Houston, Texas, United States

Site Status

Willowbend Health and Wellness Associates

Plano, Texas, United States

Site Status

Clinical Trials of Texas Incorporated Laboratory

San Antonio, Texas, United States

Site Status

Riverside Regional Medical Center

Newport News, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UL1104

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PGL4001 Versus Placebo in Uterine Myomas
NCT00755755 COMPLETED PHASE3
Esmya Versus Surgery Before IVF/ICSI
NCT04028986 ACTIVE_NOT_RECRUITING
Prescription of Letrozole for Uterine Myoma
NCT06143631 RECRUITING PHASE4